EGFR and non-small cell lung carcinoma: For Stage IB-III NSCLC resectable EGFR mutated tumors, the ADUARA trial has shown that adjuvant osimertinib significantly prolonged DFS compared with placebo.12 Treatment with osimertinib has rapidly become the standard of care in these clinical settings.